369 related articles for article (PubMed ID: 30656556)
1. The clinical effects of CYP2C19 *2 allele frequency on Palestinian patients receiving clopidogrel after percutaneous coronary intervention.
Ayesh BM; Al-Astal IR; Yassin MM
Int J Clin Pharm; 2019 Feb; 41(1):96-103. PubMed ID: 30656556
[TBL] [Abstract][Full Text] [Related]
2. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Cavallari LH; Lee CR; Beitelshees AL; Cooper-DeHoff RM; Duarte JD; Voora D; Kimmel SE; McDonough CW; Gong Y; Dave CV; Pratt VM; Alestock TD; Anderson RD; Alsip J; Ardati AK; Brott BC; Brown L; Chumnumwat S; Clare-Salzler MJ; Coons JC; Denny JC; Dillon C; Elsey AR; Hamadeh IS; Harada S; Hillegass WB; Hines L; Horenstein RB; Howell LA; Jeng LJB; Kelemen MD; Lee YM; Magvanjav O; Montasser M; Nelson DR; Nutescu EA; Nwaba DC; Pakyz RE; Palmer K; Peterson JF; Pollin TI; Quinn AH; Robinson SW; Schub J; Skaar TC; Smith DM; Sriramoju VB; Starostik P; Stys TP; Stevenson JM; Varunok N; Vesely MR; Wake DT; Weck KE; Weitzel KW; Wilke RA; Willig J; Zhao RY; Kreutz RP; Stouffer GA; Empey PE; Limdi NA; Shuldiner AR; Winterstein AG; Johnson JA;
JACC Cardiovasc Interv; 2018 Jan; 11(2):181-191. PubMed ID: 29102571
[TBL] [Abstract][Full Text] [Related]
3. CYP2C19 Genotype is an Independent Predictor of Adverse Cardiovascular Outcome in Iraqi Patients on Clopidogrel After Percutaneous Coronary Intervention.
Mohammad AM; Al-Allawi NAS
J Cardiovasc Pharmacol; 2018 Jun; 71(6):347-351. PubMed ID: 29554005
[TBL] [Abstract][Full Text] [Related]
4. Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee CR; Thomas CD; Beitelshees AL; Tuteja S; Empey PE; Lee JC; Limdi NA; Duarte JD; Skaar TC; Chen Y; Cook KJ; Coons JC; Dillon C; Franchi F; Giri J; Gong Y; Kreutz RP; McDonough CW; Stevenson JM; Weck KE; Angiolillo DJ; Johnson JA; Stouffer GA; Cavallari LH;
Clin Pharmacol Ther; 2021 Mar; 109(3):705-715. PubMed ID: 32897581
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
6. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
7. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
9. Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.
Ali ZO; Bader L; Mohammed S; Arafa S; Arabi A; Cavallari L; Langaee T; Mraiche F; Rizk N; Awaisu A; Shahin MH; Elewa H
Pharmacogenet Genomics; 2022 Jul; 32(5):183-191. PubMed ID: 35389962
[TBL] [Abstract][Full Text] [Related]
10. Effects of the
Biswas M; Sukasem C; Khatun Kali MS; Ibrahim B
Pharmacogenomics; 2022 Feb; 23(3):207-220. PubMed ID: 35042400
[TBL] [Abstract][Full Text] [Related]
11. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
[TBL] [Abstract][Full Text] [Related]
12.
Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
[TBL] [Abstract][Full Text] [Related]
13. The impact of cytochrome 450 and Paraoxonase polymorphisms on clopidogrel resistance and major adverse cardiac events in coronary heart disease patients after percutaneous coronary intervention.
Zhang Z; Chen M; Zhang L; Zhao Q
BMC Pharmacol Toxicol; 2020 Jan; 21(1):1. PubMed ID: 31900240
[TBL] [Abstract][Full Text] [Related]
14. [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention].
Wu Y; Zhang XX; Tian L; Jiang JJ; Xu L; Huang YL; Liu H; Li YS
Zhonghua Xin Xue Guan Bing Za Zhi; 2017 May; 45(5):377-385. PubMed ID: 28511321
[No Abstract] [Full Text] [Related]
15. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of
Kim JH; Lee SJ; Cha JJ; Park JH; Hong SJ; Ahn TH; Kim BK; Chang K; Park Y; Song YB; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Jeong YH; Kim HS; Kim MH; Shin ES; Lim DS;
J Am Heart Assoc; 2024 May; 13(10):e032248. PubMed ID: 38761068
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 Polymorphism in Ischemic Heart Disease Patients Taking Clopidogrel After Percutaneous Coronary Intervention in Egypt.
Shawky A; Sabit H; Nazih M; Baraka K; El-Zawahry M
J Epidemiol Glob Health; 2023 Jun; 13(2):374-383. PubMed ID: 37202608
[TBL] [Abstract][Full Text] [Related]
18. The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Saydam F; Değirmenci İ; Birdane A; Özdemir M; Ulus T; Özbayer C; Çolak E; Ata N; Güneş HV
Basic Clin Pharmacol Toxicol; 2017 Jul; 121(1):29-36. PubMed ID: 28135763
[TBL] [Abstract][Full Text] [Related]
19. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
[TBL] [Abstract][Full Text] [Related]
20. [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Zhou CF; Ren YH; Song YQ; Yi J; Han BS; Xue Q; Fu ZH; Li DY
Zhonghua Xin Xue Guan Bing Za Zhi; 2016 Apr; 44(4):309-14. PubMed ID: 27112608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
